Core Viewpoint - The brain-computer interface (BCI) industry is experiencing rapid growth, driven by advancements in technology and supportive government policies, with significant developments expected by 2026 when large-scale production is set to begin [2][3]. Industry Developments - Neuralink plans to start mass production of BCI devices in 2026, utilizing nearly fully automated surgical processes [2]. - The BCI index in the A-share market rose by 9.37%, with over 20 stocks, including companies like Botao Bio and Sanbo Brain Science, hitting the daily limit [2]. - The National Healthcare Security Administration (NHSA) has issued guidelines for BCI rehabilitation charges, which has accelerated the industry's growth [2]. Policy Support - The 14th Five-Year Plan identifies BCI as one of six key future industries, with specific pricing projects established for both invasive and non-invasive BCI technologies [3]. - New regulations from the NHSA in September 2025 will facilitate the coding of innovative medical products, further promoting BCI clinical applications [3]. Technological Breakthroughs - China has made significant strides in invasive BCI technology, becoming the second country globally to enter clinical trials for invasive BCI systems [4]. - The "North Brain No. 1" GCP multi-center clinical trial, set to launch in October 2025, will be the first to implement a high-throughput, wireless, semi-invasive BCI system with over 100 channels [4]. Competitive Landscape - The BCI industry in China is competitive, with the potential to lead globally, as companies focus on serving downstream clients, including hospitals and patients [5]. - The BCI industry has established a complete supply chain, covering upstream materials and chips, midstream signal processing, and downstream applications in healthcare and consumer products [6]. Regulatory Focus - BCI products, especially invasive types, are classified as high-risk medical devices, necessitating strict regulatory oversight [8]. - Companies like Xiangyu Medical and Aipeng Medical are actively pursuing product registrations for various BCI applications, including rehabilitation and monitoring systems [8][9].

1月5日，脑机接口板块领涨A股。截至发稿，板块涨幅超13%，个股方面，倍益康30CM涨停，三博脑 科、博拓生物、美好医疗、翔宇医疗等近20股涨停。 消息面上，马斯克日前在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备 进行"大规模生产"，并转向"更加精简和几乎完全自动化的外科手术流程"。其最新技术的设备电极丝可 直接穿过硬脑膜，而无需将其切开。 据悉，Neuralink的产品重点仍集中在治疗神经系统疾病，包括瘫痪、肌萎缩、帕金森、老年痴呆和视力 障碍。 同时，国内医疗企业在该领域不断实现技术突破。三博脑科旗下的福建三博已帮助受试者偏瘫上肢恢复 自由抓握功能；"北脑二号"也有望在2026年进入临床验证。博拓生物参股公司的植入式脑深部神经刺激 系统已进入科研性临床，产品拟2026年末启动注册。 不仅如此，资本市场对该领域的投资也较为火热，据动脉橙数据库不完全统计，2025年1—11月，我国 脑机接口领域共完成24起融资，同比增长30%。 中信建投在研报中分析称，脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来 看若能实现增强人、并与AI和机器人融合，有望打开万亿 ...

截至2026年1月5日 14:14，中证全指医疗保健设备与服务指数(H30178)上涨5.00%，样本股博拓生物 (688767)上涨20.01%，赛诺医疗(688108)上涨20.01%，三博脑科(301293)上涨20.01%，迈普医学 (301033)，美好医疗(301363)等个股均上涨。 近日，马斯克在社交媒体上表示，他的脑机接口公司Neuralink今年将开启"大规模量产"，推进全自动化 外科手术流程，让曾经的科幻黑科技正式迈入量产时代。据科普中国介绍，脑机接口是指在大脑与设备 之间建立直接连接，实现大脑与外部世界的信息交换与控制。这一技术让人们用意念操控设备成为可 能。 开源证券认为，脑机接口行业正处于技术突破、政策支持、机器人生态协同预期等多重因素驱动下的高 增蓄势期，根据Precedence Research数据，预计到2034年全球脑机接口市场规模将增长到约124亿美元， 2025-2034年CAGR为17%。在近期Neuralink规模化量产预期和技术突破的催化下，A股脑机接口相关标 的也有望受益。 国开证券指出，近期医药板块整体热点和活跃度相对较低，脑机接口领域相关进展市场关注度提升。 ...

Group 1: Quantum Technology - The "quantum + supercomputing" integration innovation platform has been established in Chengdu, deploying China's first 550-qubit coherent optical quantum computer, enabling the collaboration of classical high-performance computing and quantum computing [7][8] - The deployment of the 550-qubit quantum computer fills the gap in the central and western regions of China for quantum computing capabilities, establishing a complementary regional computing power structure with eastern regions [8][9] Group 2: Biological Manufacturing - The first sugar science key laboratory in Beijing has been approved, co-established by Huaxi Biological and Peking University, focusing on precise manufacturing and functional applications of sugars [10][11] - Huaxi Biological aims to leverage this laboratory to enhance its capabilities in synthetic biology, expanding from hyaluronic acid production to comprehensive sugar biological research [11] Group 3: Hydrogen Energy and Nuclear Fusion - The world's first 30 MW pure hydrogen gas turbine has achieved stable operation, marking a significant step in hydrogen energy transitioning from a "power consumer" to a "grid regulator" [12][13] - The EAST nuclear fusion device has confirmed the existence of a density-free regime, providing critical physical evidence for efficient operation of fusion reactors [18][19] - The Chinese Academy of Sciences has completed the manufacturing of all ITER correction coil procurement packages, marking a significant achievement in domestic R&D capabilities for nuclear fusion components [22] Group 4: Brain-Computer Interface - Neuralink plans to begin mass production of brain-computer interface devices in 2026, aiming to automate surgical procedures and enhance device performance [23][24] - The "Beijing Brain No. 1" system has been implanted in five spinal cord injury patients, achieving clinical breakthroughs, with plans for clinical trials to start in mid-2026 [26][27] - The "Guangdong-Hong Kong-Macao Greater Bay Area Brain Science and Central Nervous System Disease AI Innovation Alliance" has been launched, focusing on research and development in brain science and related technologies [28] Group 5: Embodied Intelligence - Woan Robotics has gone public in Hong Kong, focusing on household scenarios with plans to launch a humanoid household robot in January 2026 [29][30] - The "Qiyuan Q1," the world's first small-sized humanoid robot with full-body force control, has been released, targeting research and interactive applications [33][34] Group 6: Future Industry Catalysts - A table has been organized detailing key catalytic events for six future industries in 2026, including important conferences and technological milestones [36][38]

Group 1 - The core viewpoint of the news highlights the significant surge in the brain-computer interface (BCI) sector, driven by advancements and investments, particularly from Elon Musk's Neuralink, which plans to start large-scale production of BCI devices by 2026 [1] - The China Securities Regulatory Commission has included BCI in future industries, with a two-step development goal set for the next five years, indicating strong governmental support for the sector [1] - The medical device ETF (159883) has shown a notable increase of 5.54%, with a net subscription exceeding 181 million units, reflecting investor confidence in the BCI and medical technology sectors [1] Group 2 - The application of BCI technology in medical fields, particularly for mental health, rehabilitation, and health management, is expected to accelerate due to supportive policies [2] - The medical device ETF (159883) tracks the medical device sector and has a strong technological focus, with over 80% of its components coming from the Sci-Tech Innovation Board and the Growth Enterprise Market [2] - The Hong Kong medical ETF (159366) has also performed well, rising 5.34%, with significant gains in individual stocks related to brain science and medical technology [3]

Group 1 - The brain-computer interface (BCI) sector is experiencing significant growth, with companies like Neuralink and Merge Labs leading the charge in invasive and non-invasive technologies respectively [1][2] - Neuralink plans to begin large-scale production of its BCI devices in 2026, introducing a streamlined and automated surgical process that avoids traditional invasive methods [1] - Zhejiang Qiangnao Technology Co., Ltd. is emerging as a domestic unicorn in the BCI field, focusing on non-invasive technology and aiming for an IPO in mainland China or Hong Kong by 2026 [2] Group 2 - Qiangnao Technology has formed a strategic partnership with Lingyi iTech, enhancing both companies' market competitiveness and technological capabilities in the BCI and robotics sectors [2] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, driven by technological advancements and policy support [2]

Group 1: Market Performance - The medical device ETF fund (159797) surged over 5% after four consecutive days of decline, indicating a significant rebound in the market [1] - The fund saw a net subscription of 6 million shares during the trading session, with a total inflow of over 30 million yuan in the past 10 days, including 7 days of net inflow [1] - Most component stocks of the medical device ETF fund performed positively, with notable gains including Lepu Medical reaching a 20% limit up, and other companies like United Imaging and Huatai Medical rising over 4% [1] Group 2: Neuralink and Brain-Computer Interface Developments - Neuralink is expected to enter large-scale production by January 1, 2026, with nearly automated surgical operations, enhancing safety by allowing guide wires to pass through the dura mater without opening it [4] - The advancement of Neuralink's technology is anticipated to facilitate collaboration with Tesla's Optimus humanoid robot, aiming to create a "human brain + robot" ecosystem [5] - The technology is transitioning from clinical trials to commercial viability, marking a significant step in making brain-computer interfaces widely accessible [3] Group 3: Policy and Industry Trends - The National Medical Products Administration (NMPA) emphasized the strategic importance of brain-computer interfaces in a meeting held on December 18, 2025, focusing on safety, innovation in regulatory methods, and collaboration across sectors [6] - Recent clinical trials have shown promising results for brain-computer interface systems, with successful implantations and significant improvements in patients' hand functions [6] - The rapid iteration and upgrade of brain-computer interface technology are driven by advancements in signal acquisition, materials science, and multi-modal integration, paving the way for broader applications beyond medical use [7]

Core Viewpoint - The brain-computer interface (BCI) concept stocks surged on the first trading day of 2026 in the A-share market, driven by significant developments in the industry, including Neuralink's plans for mass production of BCI devices and supportive policies for high-end medical devices [1][3]. Group 1: Stock Performance - Multiple BCI-related stocks, including Aipeng Medical, Xiangyu Medical, and Meihua Medical, reached their daily limit up, with Aipeng Medical rising by 20% to 33.30 CNY [2][1]. - Other notable performers included Sainuo Medical and Hanwei Technology, which saw increases of 17.31% and 15.99%, respectively [2][1]. - The overall trend in the Hong Kong market mirrored that of the A-share market, with stocks like Nanjing Panda Electronics rising over 30% [2][1]. Group 2: Industry Developments - Elon Musk's Neuralink announced plans to begin large-scale production of BCI devices in 2026, signaling a significant advancement in the field [3]. - The integration of artificial intelligence in healthcare is accelerating, with 207 AI medical devices expected to be approved by 2025, highlighting the rapid technological progress [3]. - The global BCI market is projected to reach $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, indicating substantial growth potential [3]. - Recent policy support, including the inclusion of implantable BCI devices in a priority approval list by the National Medical Products Administration, is expected to further enhance the commercialization process [3].

Group 1: US Stock Market Predictions - The US stock market is expected to continue its bull run in 2026, with varying predictions from Wall Street firms. Morgan Stanley forecasts the S&P 500 index to rise to 7800 points, a 14% increase from the current level of 6858 points [2] - Goldman Sachs predicts the S&P 500 will reach 7600 points by the end of 2026, while Bank of America estimates a modest increase of 4-5%, targeting 7100 points [2] - Contrarily, some analysts, like Sean Williams from Motley Fool, predict a decline of at least 20% for the S&P 500, citing historical high valuations as a key concern [4] Group 2: AI Industry Outlook - There are mixed views on the AI sector, with some experts predicting a potential bubble burst due to rising interest rates, which could end the current over-investment driven by AI capital expenditures [5] - Conversely, proponents argue that AI has initiated a new industrial era, contributing significantly to GDP growth and job creation [5] - Notable companies in the AI space expected to thrive include Microsoft, Apple, Tesla, Palantir, and CrowdStrike, with significant growth potential anticipated in the coming years [7][8] Group 3: Upcoming IPOs - Major companies like OpenAI, SpaceX, and Anthropic are planning IPOs in 2026, with SpaceX currently valued at $800 billion and OpenAI at $500 billion [6] - The backlog of IPOs due to regulatory delays in 2025 is expected to be released in 2026, with over 800 unicorns in the candidate pool [6] Group 4: Quantum Computing Developments - 2026 is projected to be a milestone year for quantum computing, with expectations that quantum computers will surpass traditional computers in specific tasks [9] - However, the rise of quantum computing may disrupt the cryptocurrency market, potentially leading to a significant drop in Bitcoin prices [9] Group 5: Federal Reserve Leadership and Market Impact - Jerome Powell's potential departure from the Federal Reserve in 2026 raises concerns about future monetary policy direction, which could lead to market volatility and a potential "flight from dollar assets" [11] - The uncertainty surrounding the Fed's leadership may impact investor confidence and lead to declines in stock and bond markets [11] Group 6: Gold and Commodity Price Predictions - Economists predict a significant rise in gold prices, with some forecasting it could reach $10,000 per ounce by 2026, driven by increased institutional demand [18] - UBS estimates gold prices will peak at $5,000 per ounce in the first three quarters of 2026 before slightly declining [18] - Copper prices are also expected to rise, with Morgan Stanley predicting an average price of $12,075 per ton in 2026 [18]

据新华社旧金山电，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标 志着脑机接口技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化， 截至1月5日上午收盘，该板块指数大涨12.56%至6245.59点，超十只概念股收获"20CM"涨停。 据Neuralink官网及马斯克公开发言内容，截至2025年9月份，该公司已完成12例脑机接口设备人体植入 手术，临床试验参与者累计使用设备时长超1.5万小时，患者可通过意念实现光标操控、文字输入甚至 机械臂辅助进食等操作，设备实际运行稳定性达标率超98%。同时，第二代手术机器人实现技术升级， 将单根电极植入时间从17秒压缩至1.5秒，整体手术时长从6小时缩短至20分钟内；成本端也实现大幅下 降，单台设备植入成本从早期百万美元级降至10万美元以内，全自动化手术落地后有望进一步下探至5 万美元区间。 《证券日报》记者注意到，A股相关上市公司早已在脑机接口赛道展开布局，从设备研发到临床应用多 维度切入，试图抢占行业发展先机 ...